News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
328,531 Results
Type
Article (23221)
Company Profile (35)
Press Release (305272)
Multimedia
Podcasts (45)
Webinars (9)
Section
Business (84157)
Career Advice (910)
Deals (12993)
Drug Delivery (65)
Drug Development (47781)
Employer Resources (61)
FDA (8426)
Job Trends (7544)
News (155478)
Policy (17161)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (2144)
Academic (1)
Accelerated approval (21)
Adcomms (20)
Allergies (66)
Alliances (21438)
ALS (104)
Alzheimer's disease (1253)
Antibody-drug conjugate (ADC) (152)
Approvals (8678)
Artificial intelligence (209)
Autoimmune disease (83)
Automation (19)
Bankruptcy (145)
Best Places to Work (6684)
BIOSECURE Act (15)
Biosimilars (75)
Biotechnology (21)
Bladder cancer (127)
Brain cancer (38)
Breast cancer (367)
Cancer (2916)
Cardiovascular disease (276)
Career advice (758)
Career pathing (15)
CAR-T (157)
CDC (30)
Cell therapy (385)
Cervical cancer (28)
Clinical research (40598)
Collaboration (754)
Company closure (1)
Compensation (302)
Complete response letters (29)
COVID-19 (1750)
CRISPR (57)
C-suite (326)
Cystic fibrosis (104)
Data (4218)
Decentralized trials (1)
Denatured (8)
Depression (75)
Diabetes (324)
Diagnostics (3404)
Digital health (25)
Diversity (2)
Diversity, equity & inclusion (22)
Drug discovery (104)
Drug pricing (132)
Drug shortages (19)
Duchenne muscular dystrophy (167)
Earnings (34976)
Editorial (29)
Employer branding (5)
Employer resources (53)
Events (46765)
Executive appointments (380)
FDA (10392)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (9)
Frontotemporal dementia (19)
Funding (737)
Gene editing (124)
Generative AI (19)
Gene therapy (433)
GLP-1 (558)
Government (3554)
Grass and pollen (3)
Guidances (273)
Healthcare (11326)
HIV (38)
Huntington's disease (18)
IgA nephropathy (67)
Immunology and inflammation (93)
Immuno-oncology (27)
Indications (69)
Infectious disease (1916)
Inflammatory bowel disease (90)
Inflation Reduction Act (7)
Influenza (64)
Intellectual property (136)
Interviews (134)
IPO (6593)
IRA (27)
Job creations (1080)
Job search strategy (674)
JPM (29)
Kidney cancer (11)
Labor market (33)
Layoffs (180)
Leadership (10)
Legal (3126)
Liver cancer (48)
Longevity (4)
Lung cancer (401)
Lymphoma (275)
Machine learning (14)
Management (20)
Manufacturing (346)
MASH (173)
Medical device (5942)
Medtech (5971)
Mergers & acquisitions (6839)
Metabolic disorders (838)
Multiple sclerosis (92)
NASH (21)
Neurodegenerative disease (189)
Neuropsychiatric disorders (42)
Neuroscience (1989)
Neurotech (1)
NextGen: Class of 2026 (3813)
Non-profit (3680)
Now hiring (53)
Obesity (338)
Opinion (127)
Ovarian cancer (80)
Pain (137)
Pancreatic cancer (125)
Parkinson's disease (167)
Partnered (14)
Patents (236)
Patient recruitment (284)
Peanut (23)
People (25701)
Pharmaceutical (9)
Pharmacy benefit managers (17)
Phase 1 (12026)
Phase 2 (18156)
Phase 3 (13676)
Pipeline (3257)
Policy (194)
Postmarket research (1616)
Preclinical (5737)
Press Release (24)
Prostate cancer (135)
Psychedelics (21)
Radiopharmaceuticals (128)
Rare diseases (560)
Real estate (1962)
Recruiting (24)
Regulatory (13216)
Reports (13)
Research institute (1738)
Resumes & cover letters (145)
Rett syndrome (24)
RNA editing (5)
RSV (50)
Schizophrenia (102)
Series A (82)
Series B (68)
Service/supplier (2)
Sickle cell disease (75)
Special edition (4)
Spinal muscular atrophy (84)
Sponsored (16)
Startups (1420)
State (1)
Stomach cancer (4)
Supply chain (52)
Tariffs (59)
The Weekly (37)
Vaccines (587)
Venture capital (32)
Weight loss (200)
Women's health (46)
Worklife (4)
Date
Today (20)
Last 7 days (270)
Last 30 days (969)
Last 365 days (15415)
2026 (1596)
2025 (15574)
2024 (17865)
2023 (20350)
2022 (25508)
2021 (28092)
2020 (27952)
2019 (25481)
2018 (19062)
2017 (15143)
2016 (14617)
2015 (17390)
2014 (12402)
2013 (9760)
2012 (10561)
2011 (11163)
2010 (9680)
Location
Africa (400)
Alabama (35)
Alaska (2)
Arizona (114)
Arkansas (9)
Asia (18025)
Australia (3281)
California (5592)
Canada (1679)
China (743)
Colorado (222)
Connecticut (214)
Delaware (192)
Europe (39208)
Florida (843)
Georgia (222)
Hawaii (1)
Idaho (27)
Illinois (457)
India (37)
Indiana (259)
Iowa (7)
Japan (255)
Kansas (82)
Kentucky (23)
Louisiana (24)
Maine (35)
Maryland (794)
Massachusetts (3514)
Michigan (129)
Minnesota (235)
Mississippi (4)
Missouri (71)
Montana (16)
Nebraska (16)
Nevada (64)
New Hampshire (38)
New Jersey (1750)
New Mexico (12)
New York (1725)
North Carolina (720)
North Dakota (6)
Northern California (2729)
Ohio (192)
Oklahoma (4)
Oregon (21)
Pennsylvania (1144)
Puerto Rico (10)
Rhode Island (10)
South America (483)
South Carolina (25)
South Dakota (1)
Southern California (2304)
Tennessee (105)
Texas (902)
United States (20031)
Utah (180)
Vermont (1)
Virginia (124)
Washington D.C. (38)
Washington State (493)
West Virginia (2)
Wisconsin (50)
Wyoming (1)
328,531 Results for "national lipid association".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Regulatory
FDA Mulls National Priority Vouchers for Two Potential Merck Blockbusters: Report
The tickets could go to the lipid-lowering pill enlicitide decanoate and the antibody-drug conjugate sacituzumab tirumotecan, though a spokesperson for the HHS did not confirm the news.
December 18, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025
November 18, 2025
·
7 min read
Press Releases
Rona Therapeutics Announces Breakthrough Data on Potential Annual Dosing RNAi Therapy RN026 Targeting Lipoprotein(a) in The National Lipid Association (NLA) Scientific Sessions 2025
May 29, 2025
·
2 min read
Press Releases
Cayman Chemical and Curapath Partner to Provide Wider Access to PEG-Free Shielding Lipids for Lipid Nanoparticles
September 3, 2025
·
1 min read
Press Releases
Acuitas Therapeutics Unveils Next-Generation Lipid Nanoparticle Advancements at the 2025 mRNA Health Conference
November 18, 2025
·
6 min read
Press Releases
The American Diabetes Association Welcomes 2026 Principal Officers and Members to the National Board of Directors
January 8, 2026
·
8 min read
Gene therapy
Liver Toxicities Force Pause on Two Dose Groups of UniQure’s Mid-Stage Fabry Study
The gene therapy uses an AAV vector to restore healthy levels of the alpha-galactosidase enzyme, which is rendered dysfunctional in patients with Fabry disease, leading to the toxic build-up of lipids in cells.
February 9, 2026
·
1 min read
·
Tristan Manalac
Press Releases
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial
November 10, 2025
·
10 min read
BioCapital
Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association’s 84th Annual Scientific Sessions
Altimmune, Inc., a clinical-stage biopharmaceutical company, presented data on the effect of pemvidutide, its GLP-1/glucagon dual receptor agonist candidate in development for obesity and metabolic dysfunction-associated steatohepatitis, on cardioinflammatory lipids at the American Diabetes Association’s 84th Scientific Sessions.
June 22, 2024
·
5 min read
Press Releases
CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering
November 10, 2025
·
10 min read
1 of 32,854
Next
